Inclusion Criteria:

- Patients ≥ 18 years old

- Patient has a related family member(haploidentical) or unrelated which is 5 of 10
HLA identical match.

Standard Risk

- Acute myelogenous leukemia: CR1 with high risk cytogenetics or molecular
abnormalities such as FLT-3 ITD, or CR2 with a first remission that must have lasted
> 1 year.

- Acute Lymphocytic Leukemia: CR1, in order to be standard risk must NOT have
Philadelphia Chromosome.

- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Must be
refractory to fludarabine or fail to have a complete or partial response after
therapy with a regimen containing fludarabine (or another nucleoside analog, e.g.
2-CDA, pentostatin) or experience disease relapse within 12 months after completing
therapy with a regimen containing fludarabine (or another nucleoside analog).

- Chronic myelogenous leukemia: resistant to or intolerant of TKI, in CP1 or CP2, or
with a mutation that suggests resistance to TKI.

- Myelodysplastic Syndrome: RA, RARS, must be IPSS ≥ INT-2, Blasts <5%.

High Risk Patients:

- Acute myelogenous leukemia: Patients with CR2 are considered high risk if they have
high risk cytogenetics, or molecular abnormalities or CR1 lasted for less than 1
year. Any evidence of active disease or no blasts in an acellular marrow.

- Acute Lymphocytic Leukemia: CR1- with Ph+ disease, CR2/+ with any cytogenetics. Any
evidence of active disease.

- Chronic myelogenous leukemia- CP2/+, AP1/+, resistant or intolerant to TKI.

- Hodgkin's or Non Hodgkin's lymphoma- Disease recurrence following an autologous
transplant, or high risk disease not thought to benefit from autologous transplant.

- Chronic lymphocytic leukemia- that is resistant to fludarabine, and never has been in
remission or with stable disease/progressive disease

- Multiple myeloma: Must have had prior treatment. Patients with high risk cytogenetics
in CR1 may be considered. Previous autologous transplant allowed, however, must have
been greater than 6 months prior to undergoing this transplant.

- Myelodysplastic syndrome: RAEB, CMML

- Other Myeloproliferative disorders including myelofibrosis, spent phase p Vera or
Essential thrombocytosis.

Exclusion Criteria:

- Patients <18 years old Disease related criteria

- APML, presence of t(15,17) in first CR

- Patients with good risk AML, for example t(8;21), or inv 16, or normal
cytogenetics with FLT-3-ITD negative, NPM-1 positive disease in 1st CR

- MDS IPSS < INT-2 Miscellaneous Criteria

- Recipients who have a matched related sibling or unrelated donor

- If recipient has evidence of anti-HLA antibodies directed against cord or
haplo-donor as determined byflowPRA.

Underlying health criteria:

- Zubrod performance status > 2 (see Appendix E)

- Life expectancy is limited to less than 8 weeks by concomitant illness

- Patients with severely decreased LVEF (EF < 40%)

- Impaired pulmonary function tests (PFT's) (FVC, FEV1, DLCO < 45% predicted)

- Estimated Creatinine Clearance <50 ml/min

- Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal

- Evidence of chronic active hepatitis or cirrhosis

- HIV-positive

- Patient is pregnant

- Patient or guardian not able to provide informed consent